Abeona Therapeutics Inc (ABEO) News & EventsABEOAbeona Therapeutics Inc

Abeona Therapeutics Q2 Revenue at $11.38M

Reports Q2 revenue $11.38M, consensus $12.16M. "Our confidence in ZEVASKYN's substantial opportunity is reinforced by our launch progress and experience to date as we engage with a growing number of patients and expand our QTC network," said Vish Seshadri, Chief Executive Officer of Abeona Therapeutics. "As early real-world experience with ZEVASKYN matures across activated sites, we expect to drive broader adoption and long-term growth."

Abeona Announces Cincinnati Children's as Seventh Qualified Treatment Center for Zevaskyn

Abeona Therapeutics announced the activation of Cincinnati Children's as the seventh Qualified Treatment Center for the administration of Zevaskyn. Zevaskyn is an autologous gene-modified cellular sheet therapy indicated for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa. "Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC. We look forward to collaborating with Cincinnati Children's to make ZEVASKYN available to RDEB patients in need," said Madhav Vasanthavada, chief commercial officer of Abeona.

Abeona Therapeutics Q1 Revenue at $8.72M

Reports Q1 revenue $8.72M, consensus $4.94M. "We are excited that an increasing number of patients at our QTCs are getting scheduled for ZEVASKYN slots this quarter," said Vish Seshadri, president and CEO of Abeona Therapeutics. "We're encouraged by the recent acceleration of onboarding efforts of QTCs to activate, so they can begin to treat patients with ZEVASKYN."